This DNA-based therapy may help solve one of cardiology’s biggest adherence problems
Industry Buzz
PPRHs, especially HpE12, are therapeutic oligonucleotides with many advantages, including low cost of synthesis, stability and lack of immunogenicity. In addition, such a PPRH-based approach against PCSK9 would not lead to side effects such as the myopathies associated with statin therapy.
—The study's authors, via a press release
Researchers from the University of Barcelona and the University of Oregon are reporting an intriguing new approach to lowering LDL that could eventually broaden the cardiology toolkit beyond statins and PCSK9 inhibitors.
In preclinical studies, an experimental DNA-based therapy reduced LDL cholesterol levels by nearly 50%, raising early questions about whether gene-targeted approaches may someday complement—or, for some patients, potentially replace—traditional lipid-lowering strategies.[]
A new approach to targeting PCSK9
The therapy targets PCSK9, a protein cardiologists know well for its central role in LDL receptor degradation. Current therapies such as evolocumab, alirocumab, and inclisiran already exploit this pathway effectively.[]
One candidate molecule, called HpE12, produced particularly strong results in lab models. By reducing PCSK9 expression, the therapy enabled more LDL receptors to remain active on hepatocyte surfaces, significantly enhancing LDL clearance and lowering circulating LDL cholesterol by close to 50%.[][]
Why cardiologists are paying attention
The researchers suggest PPRHs may offer several theoretical advantages, including lower production costs, improved molecular stability, and lack of immunogenicity compared with biologic therapies.[][]
“PPRHs, especially HpE12, are therapeutic oligonucleotides with many advantages, including low cost of synthesis, stability and lack of immunogenicity. In addition, such a PPRH-based approach against PCSK9 would not lead to side effects such as the myopathies associated with statin therapy,” the study’s authors said in a press release.[]
There is also interest in whether these agents could help patients who struggle with statin-associated muscle symptoms or who remain reluctant to use injectable biologics.
The study also highlights how rapidly cardiovascular therapeutics are shifting toward precision genetic medicine. Inclisiran introduced the concept of infrequent RNA-based LDL lowering into routine care, and CRISPR-based liquid therapies are already advancing through clinical development.
PPRHs push that evolution a step further by targeting transcription itself. If future studies demonstrate durable efficacy and acceptable safety in humans, the platform could become particularly relevant for patients with hypercholesterolemia, severe statin intolerance, or refractory residual risk despite maximally tolerated therapy.[]
Important caveats before clinical adoption
It’s important to keep the findings in perspective. This remains an early stage, preclinical study. There are many unanswered questions regarding long-term safety, hepatic delivery, off-target genetic effects, dosing durability, and scalability.[]
And as with every emerging lipid therapy, LDL reduction alone will not be enough to drive adoption. Cardiologists will ultimately want to see hard cardiovascular outcomes data demonstrating reductions in myocardial infarction, stroke, and cardiovascular mortality before considering these therapies truly practice-changing.
Still, the findings offer another glimpse at where preventive cardiology may be heading: toward increasingly precise, gene-directed therapies capable of modifying cardiovascular risk at its biologic source rather than simply managing downstream effects.